According to atai Life Sciences, a single dose of an investigational intranasal formulation of mebufotenin benzoate, a ...

An experimental psychedelic therapy from the U.K. company Beckley Psytech significantly reduced symptoms of ...

Despite a significant improvement in symptoms, around 20% of patients discontinued treatment due to adverse events.

Compared with placebo, pramipexole added to antidepressants reduces symptoms significantly at 12 weeks in treatment-resistant depression, a trial finds.

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Introduction Major depressive disorder (MDD) is a major global healthcare challenge. This is, in part, due to the lack of treatment response and chronic course of MDD. Such a course of illness is ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the therapy.

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a ...